This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
Ultimovacs Asa
Q42024
1/31/2025
Hans-Vasper Eid
CFO and Interim CEO of Ultimovax
Good morning and welcome to this webcast, where we will give a business update and present the results of Ultimovax for the fourth quarter of 2024. My name is Hans-Vasper Eid, and I'm the CFO and interim CEO of Ultimovax. With me today, I have Namir Hassan, CEO of Celuna Immunotherapy, who will become the CEO of the new Celuna Group. Our chief medical officer, Jens Børheim, will also be available during the Q&A session. You may post questions during the presentation through the web platform for this webcast.
Operator
Presentation Operator
Next slide, please. As a listed company, we would like to share our disclaimer.
Operator
Presentation Operator
Next slide, please.
You're reading a preview of the ULTMF Q4 2024 earnings call.
Free account.
Disclaimer